Back to results
US 11,027,006 B2Granted
Adenoviral vector vaccine
AssigneeVAXum, LLC
InventorsAlbert B. Deisseroth, Lixin Zhang
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeVAXum, LLC
InventorsAlbert B. Deisseroth, Lixin Zhang
Estimating the term…
Provided are adenoviral vectors for generating an immune response to antigen. The vectors comprise a transcription unit encoding a secretable polypeptide, the polypeptide comprising a secretory signal sequence upstream of a tumor antigen upstream of CD40 ligand, which is missing all or substantially all of the transmembrane domain rendering CD40L secretable. Also provided are methods of generating an immune response against cells expressing a tumor antigen by administering an effective amount of the invention vector. Further provided are methods of generating an immune response against cancer expressing a tumor antigen in an individual by administering an effective amount of the invention vector. Still further provided are methods of generating immunity to infection by human papilloma virus (HPV) by administering an effective amount of the invention vector which encodes the E6 or E7 protein of HPV. The immunity generated is long term.
A viral expression vector composition for generating an antigen specific cellular immune response against cancer cells which are positive for a target antigen by promoting activation of an individual's dendritic cells, said viral expression vector composition comprising a transcription unit encoding a fusion protein comprising a secretable CD40 ligand extracellular domain fused to a secretory signal sequence and a target antigen, wherein the target antigen is attached by a linker to an amino-terminus of the extracellular domain of said CD40 ligand.
A viral expression vector vaccine composition configured for generating an antigen specific cellular immune response against a target antigen by promoting activation of an individual's dendritic cells, comprising a transcription unit encoding a secretable fusion protein including (i) an extracellular domain of the CD40 ligand having an amino terminus, (ii) a secretory signal sequence and (iii) a target antigen, wherein the target antigen is attached by a linker to the amino terminus of said CD40 ligand.
Dependencies are inferred from the claim text.